ABSTRACT
The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the animal reflux-inflammation models for Barrett's esophagus and esophageal adenocarcinoma; genomic/epigenomic analyses; eflornithine-based combinations; the molecular derangements that promote neoplastic transformation; the role of COX-2 inhibitors, proton pump inhibitors, and phase II trials in Barrett's adenocarcinoma; statins in chemoprevention and treatment of esophageal cancer; and biomarkers as potential targets in Barrett's adenocarcinoma.
Subject(s)
Antineoplastic Agents/therapeutic use , Esophageal Neoplasms/diagnosis , Esophageal Neoplasms/prevention & control , Animals , Barrett Esophagus/diagnosis , Barrett Esophagus/metabolism , Barrett Esophagus/prevention & control , Biomarkers, Tumor/metabolism , Cell Transformation, Neoplastic/metabolism , Cyclooxygenase 2 Inhibitors/therapeutic use , Eflornithine/therapeutic use , Esophageal Neoplasms/metabolism , Gastroesophageal Reflux/diagnosis , Gastroesophageal Reflux/metabolism , Gastroesophageal Reflux/prevention & control , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Paris , Proton Pump Inhibitors/therapeutic useABSTRACT
The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on translational research on Barrett's esophagus that address evidence for genetic instability in esophageal cancer; the role of microsatellite instability; the use of histologic and serum Doublecortin-like kinase 1 expression for progression of Barrett's esophagus to adenocarcinoma; the oxidative stress in Barrett's tumorigenesis; the genomic alterations in esophageal cancer; in vivo modeling in Barrett's esophagus; epigenetic and transcriptional regulation in Barrett's esophagus and esophageal adenocarcinoma; and normal and disordered regeneration in Barrett's esophagus.